课题基金 / 基金详情

Study for mechanism of insulin sensitizer using a cDNA subtraction technique

Study for mechanism of insulin sensitizer using a cDNA subtraction technique
利用cDNA消减技术研究胰岛素增敏剂的作用机制
批准号:
11671118
负责人:
MATSUTANI Akira
金额:
$2.18万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1999
资助国家:
日本
项目状态:
已结题
起止时间:
1999 至 2000

项目摘要

项目成果

MATSUTANI Akira的其他基金

相似基金

相关文献

中文摘要
翻译
1999年10月使用基因芯片寻找噻唑烷二酮敏感基因胰岛素增敏剂噻唑烷二酮被认为主要通过增强胰岛素对骨骼肌细胞的作用而发挥抗糖尿病作用。PPARg是噻唑烷二酮的靶标,在肝细胞以及脂肪细胞和肌肉细胞中表达。为探讨噻唑烷二酮对小鼠肝细胞基因表达的影响,将小鼠原代肝细胞分别与罗格列酮(5 μmol)和新型噻唑烷二酮化合物MCC 555(25 μmol)孵育,观察噻唑烷二酮对小鼠肝细胞基因表达的影响。培养24小时后,从培养的肝细胞中纯化mRNA。mRNA经荧光标记后与基因芯片杂交。比较对照组、罗格列酮组和MCC55组之间的信号差异,并寻找噻唑烷二酮修饰表达的基因,发现TC20874、TC21818、TC25018、TC26141、TC30984等20多个基因表达水平与对照组相比有显著性差异,其中TC20874、TC21818、TC25018、TC26141和TC30984基因表达水平与对照组相比有显著性差异。 关于我们 用噻唑烷二酮上调ONS。另一方面,包括TC 14248、TC 14302、TC 14653、TC 14842、TC 15141在内的100多个基因被鉴定为噻唑烷二酮下调表达的基因。进一步研究发现,曲格列酮可增加体外培养细胞VEGF的表达,并可增加人血浆VEGF水平,其中包括TC 20874、TC 21818、TC 25018、TC 26141、TC 30984等20多个基因的表达被噻唑烷二酮上调。另一方面,包括TC 14248、TC 14302、TC 14653、TC 14842、TC 15141在内的100多个基因被鉴定为噻唑烷二酮下调表达的基因。此外,还发现曲格列酮可增加培养细胞中VEGF的表达,而处方曲格列酮可增加人血浆VEGF水平。尽管噻唑烷二酮在体外使用细胞系影响单核细胞分化,但当胰岛素增敏剂用于临床时,对白色血细胞的影响尚不清楚。因此,我们试图观察吡格列酮(另一种噻唑烷二酮)临床应用后2型糖尿病患者白色血细胞表面标志物和血清细胞因子水平的变化。我们正在分析数据。少
英文摘要
1999〜Search for thiazolidinedione-sensitive genes using GeneChipInsulin sensitizer, thiazolidinedione, is thought to exert an antidiabetic effect by poteniating the insulin action chiefly on skeletal muscle cells. PPARg, a target of thiazolidinedione, is expressed in hepatocytes as well as adipocytes and muscle cells. To elucidate the mechanism of thiazolidinedione, effects of thiazolidinedione on gene expression of mouse hepatocytes were examined.Mouse primary hepatocytes were incubated in medium in the presence or the absence of 5 μmol of rosiglitazone or 25 μmol of MCC555, a new thiazolidinedione. After 24 hr of culture, mRNA was purified from cultured hepatocytes. mRNA was labelled with fluoressence and was hybridized with GeneChip. Signals were compared among control, rosiglitazone and MCC55, and genes whose expressions were modified with thiazolidinedione were searched.More than 20 genes including TC20874, TC21818, TC25018, TC26141, TC30984 were identified as genes whose expressi … More ons were upregulated with thiazolidinedione. On the other hand, more than 100 genes including TC14248, TC14302, TC14653, TC14842, TC15141 were identified as genes whose expression were downregulated with thiazolidinedione. Furtheremore, it was found that expression of VEGF was increased with troglitazone in cultured cellS and plasma VEGF levels were increased in human with prescribed troglitazone.More than 20 genes including TC20874, TC21818, TC25018, TC26141, TC30984 were identified as genes whose expressions were upregulated with thiazolidinedione. On the other hand, more than 100 genes including TC14248, TC14302, TC14653, TC14842, TC15141 were identified as genes whose expression were downregulated with thiazolidinedione. Furtheremore, it was found that expression of VEGF was increased with troglitazone in cultured cellS and plasma VEGF levels were increased in human with prescribed troglitazone.Though thiazolidinedione was reported to affect monocyte differentiation in vitro using cell lines, nothing is known about the effect on white blood cells when insulin sensitizer is clinically used. We, therefore, attempted to see changes of surface markers on white blood cells and serum cytokine levels from patient with type2 diabetes after pioglitazone, another kind of thiazolidinedione, was clinically used. We are now analyzing data. Less
期刊论文(7)
专著(0)
科研奖励(0)
会议论文
Ohji T: "Over expression of human insulinoma PFK_2/P2,6DPase in rat Primary cultured hepatocytes"the proceedings of 10th Japan/Korea Diabetes Mellitus Symposium,Japan 8-9 Oct 1999. (in press).
Ohji T:“大鼠原代培养肝细胞中人胰岛素瘤 PFK_2/P2,6DPase 的过度表达”,第 10 届日本/韩国糖尿病研讨会的会议记录,日本 1999 年 10 月 8-9 日。(印刷中)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Ohji T: "Diabete Mellitus : Recent Advances for the 21th."Elsvier, Editors : Shichiri M, Shinn SH, Hotta N.. 7 (2000)
Ohji T:“糖尿病:21 世纪的最新进展”。Elsvier,编辑:Shichiri M、Shinn SH、Hotta N.. 7 (2000)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Emoto M: "Troglitazone treatment increases plasma vascular endotherial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes."Diabetes. 50(In press). (2001)
Emoto M:“曲格列酮治疗可增加糖尿病患者的血浆血管内皮生长因子及其在 3T3-L1 脂肪细胞中的 mRNA。”糖尿病。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Ohji T: "Overexpression of human insulinorna PFK2/F2, 6DPase in rat primary cultured hepatocytes : key role of F2, 6DP in glucagon effects on hepatic glucose metabolism."Diabete Mellitus : Recent Adcances for the 21th., Elsvier, Editors : Shichiri M, Shin
Ohji T:“大鼠原代培养肝细胞中人胰岛素 PFK2/F2、6DP 酶的过度表达:F2、6DP 在胰高血糖素对肝葡萄糖代谢影响中的关键作用。”糖尿病:第 21 期最新进展。,爱思唯尔,编辑:七里 M
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
6
    Deficiency of glucokinase gene expression and NIDDM
    • 批准号:
      06671034
    • 项目类别:
      Grant-in-Aid for General Scientific Research (C)
    • 资助金额:
      $1.15万
    • 财政年份:
      1994
    • 负责人:
      MATSUTANI Akira
    • 依托单位:
    Elucidation of mechanism for diabetogenesis in Wistar Fatty rats
    • 批准号:
      04671483
    • 项目类别:
      Grant-in-Aid for General Scientific Research (C)
    • 资助金额:
      $1.28万
    • 财政年份:
      1992
    • 负责人:
      MATSUTANI Akira
    • 依托单位:
    海外基金